Enliven Therapeutics, Inc. (ELVN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 872.63M |
| Enterprise Value | 774.13M |
| P/E Ratio | -36.48 |
| PEG Ratio | -1.84 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 4.42 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -39.12 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | 0 |
| Operating Margin | 0 |
AD
Management Effectiveness
| Return On Assets | -0.12 |
| Return On Equity | -0.19 |
Income Statement
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -263,000 |
| EBITDA | -103.43M |
| Net Income | -103.69M |
| Diluted EPS | -1.83 |
Balance Sheet
| Total Cash | 895.16M |
| Total Cash/Share | 13.53 |
| Total Debt | 1.51M |
| Total Debt/Equity | 0 |
| Current Ratio | 64.07 |
| Book Value Per Share | 13.53 |
Price History
| 52-Week Change | 186.91 |
| 52-Week High | 62.32 |
| 52-Week Low | 14.79 |
| Moving Average 50 Days | 52.36 |
| Moving Average 200 Days | 35.44 |
Statistics
| Average Volume | 1.43M |
| Shares Outstanding | 71.44M |
| % Held by Institutions | 128.23 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:4 |
| Last Split Date | February 24, 2023 |
AD
